Esomeprazole Strontium — Active Pharmaceutical Ingredient

Esomeprazole Strontium is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: CAPSULE, DELAYED RELEASE. Routes: ORAL.

This content is for informational purposes only. Always consult a healthcare professional.

Esomeprazole Strontium (1 brand name, 1 dosage form, 1 route)

Available dosage forms: CAPSULE, DELAYED RELEASE.

Routes of administration: ORAL.

Brand Names

  • ESOMEPRAZOLE STRONTIUM

Dosage and Administration

Esomeprazole strontium is supplied as delayed-release capsules for oral administration. The recommended dosages are outlined in Table 1. Esomeprazole strontium should be taken at least one hour before meals. The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment. Table 1: Recommended Dosage Schedule of Esomeprazole Strontium Delayed-Release Capsules Indication Dose Frequency Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis 24.65 mga or 49.3 mgb Once Daily for 4 to 8 Weeks* Maintenance of Healing of Erosive Esophagitis 24.65 mga Once Daily** Symptomatic Gastroesophageal Reflux Disease 24.65 mga Once Daily for 4 Weeks*** Risk Reduction of NSAID-Associated Gastric Ulcer in Adults 24.65 mga or 49.3 mgb Once Daily for up to 6 months** H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy: esomeprazole strontium 49.3 mgb Once Daily for 10 Days Amoxicillin 1000 mg Twice Daily for 10 Days Clarithromycin 500 mg Twice Daily for 10 Days Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome in Adults 49.3 mg†b ‡Twice Daily *[See Clinical Studies (14.1).] The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4 to 8 weeks, an additional 4 to 8 weeks of treatment may be considered. **Controlled studies did not extend beyond six months. ***If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered. †The dosage of esomeprazole strontium in patients with pathological hypersecretory conditions varies with the individual patient. Dosage regimens should be adjusted to individual patient needs. ‡Doses up to

Contraindications

Esomeprazole strontium is contraindicated in patients with known hypersensitivity to proton pump inhibitors. Hypersensitivity reactions, e.g., angioedema and anaphylactic shock, have been reported with esomeprazole use. For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with esomeprazole strontium, refer to the CONTRAINDICATIONS section of their package inserts.

Mechanism of Action

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion.

Overdosage

A single oral dose of esomeprazole at 510 mg/kg (about 103 times the human dose on a body surface area basis), was lethal to rats. The major signs of acute toxicity were reduced motor activity, changes in respiratory frequency, tremor, ataxia, and intermittent clonic convulsions. The symptoms described in connection with deliberate esomeprazole overdose (limited experience of doses in excess of 240 mg/day) are transient. Single doses of 80 mg of esomeprazole were uneventful. Reports of overdosage with omeprazole in humans may also be relevant. Doses ranged up to 2,400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience (see omeprazole package insert - Adverse Reactions). No specific antidote for esomeprazole is known. Since esomeprazole is extensively protein bound, it is not expected to be removed by dialysis. In the event of overdosage, treatment should be symptomatic and supportive. As with the management of any overdose, the possibility of multiple drug ingestion should be considered. For current information on treatment of any drug overdose contact a Poison Control Center at 1-800-222-1222.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.